AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors, even the big and sophisticated ones, can often get it wrong due to short-termism driving their decisions. However, independent directors of a company can save them from making rash calls by considering the long-term prospects of the business and its ability to deliver shareholder value.

AstraZeneca is now bigger than Pfizer, but what's the secret of CEO Soriot's success?

Pfizer

British pharma giant AstraZeneca PLC (LSE:AZN) has overtaken US counterpart Pfizer plc in terms of market capitalisation in the days leading up to the former's quarterly earnings call on Thursday. FTSE 100 constituent AstraZeneca has a market value of £189bn, having added 5.7% in 2023, while Pfizer on the New York Stock Exchange has dipped over 20% year to date, bringing its market value to around £182bn.

AstraZeneca overtakes former takeover rival Pfizer

GlaxoSmithKline

The FTSE 100's biggest company reports next week, AstraZeneca PLC (LSE:AZN) stepping up with a first-quarter trading update on Thursday, preceded by a day by its former close rival GSK PLC (LSE:GSK, NYSE:GSK).   For £187bn AZ, sales momentum remains key for investors, analysts reckon, with the company having given guidance for low-to-mid single digit total revenues growth, or low-double digits if excluding Covid medicines.

AstraZeneca results arrive with focus on drug trials, while GSK still faces Zantac overhang

Ionis Pharma

AstraZeneca and Ionis recently shared promising phase 3 clinical trials for eplontersen. If approved, the drug candidate could top $1 billion in annual sales -- split between the two companies.

Could This Rare-Disease Drug Candidate Become a Blockbuster?

Pfizer Vs. AstraZeneca: Which Is Better For Long-Term Investors?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes?

Astrazeneca (AZN) is a Top Dividend Stock Right Now: Should You Buy?

Smith & Nephew

Sanofi

You don't see financial TV channels dedicated to minute-by-minute coverage of dividend yield or increases, but for investors in companies like Sanofi (NASDAQ: SNY), AstraZeneca plc (NASDAQ: AZN), and Smith & Nephew plc (NYSE: SNN), there should be at least a little excitement about intrinsically boosting your stock's return every quarter.

3 Healthcare Dividend Payers With Big Price Growth

LOS ANGELES , April 14, 2023 /PRNewswire/ -- ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent and radiopharmaceutical therapies (RPT) announces a poster presentation at AACR 2023 (# 3577 / 2 Poster PET, MRI, and CT Imaging April 18, 2023) of an independent analysis undertaken by AstraZeneca (LSE/STO/Nasdaq: AZN), on data from ImaginAb's IAB-CD8-201 'iCorrelate' Phase II study. The analysis shows baseline and early on-treatment CD8 ImmunoPET/CT may be able to distinguish responders from non-responders in patients receiving standard of care immune checkpoint blockade (ICB) therapy.

New analysis of Phase II data at AACR assesses ImaginAb's investigational CD8 ImmunoPET technology's ability to predict response in immunotherapy

AstraZeneca PLC (LSE:AZN) saw its full-year earnings per share forecasts raised by Barclays analysts, despite hints that upcoming trial updates were “dominating the narrative”. Dubbing the FTSE 100-listed biotechnology company ‘overweight,' Barclays forecasted AstraZeneca's core earnings per share to hit US$7.38 this year and US$8.67 in 2024, up from US$7.13 and US$8.65 anticipated previously.

AstraZeneca earnings per share forecasts raised by Barclays

AstraZeneca (AZN) and Sanofi (SNY) revise the contractual terms of the agreement for Beyfortus. Sanofi will have full commercial control of Beyfortus in the United States.

AstraZeneca (AZN), Sanofi Simply RSV Antibody Agreement Terms

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase five real-world evidence (RWE) studies from its industry-leading Cardiovascular, Renal and Metabolism (CVRM) portfolio, reinforcing its commitment to advancing science in chronic kidney disease (CKD) and hyperkalemia (HK), at the National Kidney Foundation (NKF) Spring Clinical Meeting April 11-15, 2023.

AstraZeneca reinforces commitment to advancing science for patients with chronic kidney disease and hyperkalemia at NKF Spring Clinical Meeting 2023

AstraZeneca PLC (LSE:AZN), Swedish Orphan Biovitrum AB (Sobi) and Sanofi have updated and simplified their agreements relating to the development and commercialisation of nirsevimab in the US. As a result of this simpler agreement, AstraZeneca will record a gain of US$0.7bn, to be recognised in core other operating income in 2023.

AstraZeneca releases US$0.7bn after simplifying US RSV deal

McDonald's

Dow Jones component McDonald's hits new high ahead of earnings as shares trade in a buy zone. The post McDonald's, U.K. Pharma Giant Hit New Highs appeared first on Investor's Business Daily.

McDonald's, U.K. Pharma Giant Hit New Highs

Encouraging Phase III DUO-O trial results from a new combination of AstraZeneca's Imfinzi and Lynparza drugs plus Avastin in advanced ovarian cancer could give a boost to expectations for the UK pharma's cancer treatments. While only a headline announcement, Shore Cap said the benefit was demonstrated in patients without BRCA mutations, potentially broadening the scope of Imfinzi beyond its approved use in HRD+ patients.

AstraZeneca premium justified by long-term potential says broker

Interim data from a late-stage study shows that AstraZeneca's (AZN) cancer drugs, Lynparza and Imfinzi improved progression-free survival in certain patients with advanced ovarian cancer.

AstraZeneca's (AZN) Drug Combo Meets Ovarian Cancer Study Goal

AstraZeneca said Wednesday a combination of its drugs Lynparza and Imfinzi met the goal of a key study, leading AZN stock to surge. The post Medical Behemoth AstraZeneca Flirts With Breakout On Fresh Hope In Ovarian Cancer appeared first on Investor's Business Daily.

Medical Behemoth AstraZeneca Flirts With Breakout On Fresh Hope In Ovarian Cancer

AstraZeneca PLC (LSE:AZN), the Anglo-Swedish pharmaceutical giant, has announced encouraging results from a planned interim analysis of its DUO-O phase III trial. The study assessed the combination of its drugs Lynparza and Imfinzi, along with chemotherapy, and a treatment called bevacizumab.

AstraZeneca drug combo improves ovarian cancer survival rate

HONG KONG--(BUSINESS WIRE)--Hong Kong Science and Technology Parks (HKSTP) continues to strengthen the strategic partnership with AstraZeneca, one of the world's leading pharmaceutical companies. The goal of this collaboration is to position Hong Kong and the Greater Bay Area as a trailblazer in life science innovation and serve as a model for the region.

HKSTP and AstraZeneca signing MOU on Strategic Collaboration

NVIDIA

The Harbor Capital Appreciation Fund (Trades, Portfolio) disclosed its equity portfolio for the first quarter of 2023 last week.

Harbor Capital Appreciation Fund Buys AstraZeneca, Ups Nvidia Holding

CHMP recommends AstraZeneca's (AZN) Ultomiris for the treatment of patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.

AstraZeneca (AZN) Ultomiris Gets CHMP Nod for New Rare Disease

This is Why Astrazeneca (AZN) is a Great Dividend Stock

Automatic Data Processing

Arcos Dorados Hlds

Ford Motor Company

QUALCOMM

Texas Roadhouse

Welltower

When it comes to dividend-paying growth stocks, it can be difficult to find names that are both high-growth and high-yield. This makes sense, given that companies with high dividend yields are typically paying out a large portion of their earnings as a dividend, leaving little capital to fund growth.

7 Growth Stocks That Pay Generous Dividends

Compass Group PLC

CHARLOTTE, N.C.--(BUSINESS WIRE)--Compass Group and AstraZeneca announce a new, forward-thinking partnership for integrated facilities management focused on workplace experience.

Compass Group and AstraZeneca Expand Activities Focused on Innovation and Shared Success

Albemarle

Lockheed Martin

Newmont Mining

Apple

Chevron

The financial sector-driven panic sent investors to the refuge of safe assets, including blue-chip stocks. In general, blue-chip stocks have a low beta and this supports capital preservation.

7 Blue-Chip Stocks to Buy for Capital Preservation

Visa

York Water

Dividend stocks tend to be profitable and time-tested, which can provide an added layer of safety for conservative investors. These three income stocks possess the sustained catalysts necessary to grow an initial investment of $400,000 by 150%, including payouts, by 2030.

3 Exceptionally Safe Dividend Stocks That Can Turn $400,000 Into $1 Million by 2030

News for AstraZeneca Stock (AZN)